Unformatted text preview: number GAL-INT-18. Available: http:⁄⁄www. clinicalstudyresults.org/documents/ company-study_96_2.pdf Accessed 28 February 2006. 33. US Food and Drug Administration [FDA] (2005) Alert for healthcare professionals on galantamine hydrochloride (marketed as Reminyl). Rockville (Maryland): FDA. Available: http:⁄⁄www.fda.gov/cder/drug/ InfoSheets/HCP/galantamineHCP.htm. Accessed 16 February 2006. 34. Takeda A, Loveman E, Clegg A, Kirby J, Picot J, et al. (2006) A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease. Int J Geriatr Psychiatry 21: 17–28. 35. Raschetti R, Maggini M, Sorrentino GC, Martini N, Caffari B, et al. (2005) A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer’s disease. Eur J Clin Pharmacol 61: 361–368. April 2006 | Volume 3 | Issue 4 | e140...
View Full Document
- Spring '10
- Clinical trial, Mild Cognitive Impairment, donepezil